|
| | Publication Year | Title | Author(s) |
| 1 | May-2023 | Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study. | Manos, Kate ; Chong, Geoffrey ; Keane, Colm; Lee, Sze Ting ; Smith, Charmaine; Churilov, Leonid ; McKendrick, Joseph; Renwick, William; Blombery, Piers; Burgess, Melinda; Nelson, Niles Elizabeth; Fancourt, Tineke ; Hawking, Joanne; Lin, Wendi; Scott, Andrew M ; Barraclough, Allison ; Wight, Joel C ; Grigg, Andrew P ; Fong, Chun Yew ; Hawkes, Eliza A |
| 2 | Nov-2020 | Routine Blood Tests in Asymptomatic Patients With Indolent Lymphoma Have Limited Ability to Detect Clinically Significant Disease Progression. | Piercey, Oliver A; Loh, Zoe ; Chan, Joanna; Chong, Geoffrey ; Grigg, Andrew P ; Cheema, Steven ; Gill, Gurjot; Whybird, Matthew; Cushion, Tania; Hawkes, Eliza A |
| 3 | Oct-2019 | Comprehensive geriatric assessment is useful in an elderly Australian population with diffuse large B-cell lymphoma receiving rituximab-chemotherapy combinations. | Ong, Doen Ming; Ashby, Michael; Grigg, Andrew P ; Gard, Grace; Ng, Zi Y; Huang, Huayi Ellen; Chong, Yee Shuen; Cheah, Chan Yoon; Devitt, Bianca; Chong, Geoffrey ; Loh, Zoe ; Mo, Allison ; Hawkes, Eliza A |
| 4 | May-2018 | Limited utility of routine chest X-ray in initial evaluation of neutropenic fever in patients with haematological diseases undergoing chemotherapy. | Estacio, Ortis; Loh, Zoe ; Baker, Amy ; Chong, Geoffrey ; Grigg, Andrew P ; Churilov, Leonid ; Hawkes, Eliza A |
| 5 | 2018 | Prognostication of diffuse large B-cell lymphoma in the molecular era: moving beyond the IPI. | Wight, Joel C ; Chong, Geoffrey ; Grigg, Andrew P ; Hawkes, Eliza A |
| 6 | 2018 | Routine blood investigations have limited utility in surveillance of aggressive lymphoma in asymptomatic patients in complete remission. | Hawkes, Eliza A ; Loh, Zoe ; Estacio, Ortis; Chong, Geoffrey ; Ha, Francis J; Gilbertson, Michael; Grigg, Andrew P |
| 7 | Feb-2017 | Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14 | Hertzberg, Mark; Gandhi, Maher K; Trotman, Judith; Butcher, Belinda; Taper, John; Johnston, Amanda; Gill, Devinder; Ho, Shir-Jing; Cull, Gavin; Fay, Keith; Chong, Geoffrey ; Grigg, Andrew P ; Lewis, Ian D.; Milliken, Sam; Renwick, William; Hahn, Uwe; Filshie, Robin; Kannourakis, George; Watson, Anne-Marie; Warburton, Pauline; Wirth, Andrew; Seymour, John F; Hofman, Michael S; Hicks, Rodney J; Australasian Leukaemia and Lymphoma Group (ALLG)
|
| 8 | 20-Jan-2017 | Is Upfront Escalated BEACOPP for Advanced Hodgkin Lymphoma Becoming a Distant Memory? | Hawkes, Eliza A ; Chong, Geoffrey ; Grigg, Andrew P |
| 9 | 1-May-2015 | Programmed cell death-1 inhibition in lymphoma. | Hawkes, Eliza A ; Grigg, Andrew P ; Chong, Geoffrey |
| 10 | 17-Feb-2015 | Diagnostic medical radiation exposure in surveillance of aggressive lymphoma: clinical trial design should reflect clinical practice. | Hawkes, Eliza A ; Chong, Geoffrey ; Grigg, Andrew P |
Loading...
2
0
20
0
false